-+ 0.00%
-+ 0.00%
-+ 0.00%

Sigmakoki (TSE:7713) Stock Rallies As Profit Rebound Catches Up

Simply Wall St·10/11/2026 22:29:15
语音播报

Sigmakoki’s share price has already sprinted ahead, with investors bidding the stock up strongly over the past month. Today’s earnings story is really about profits catching up with the optimism. Basic earnings per share for Q1 2027 came in at ¥52.67 and net income reached ¥373 million, both higher than any single quarter in the past fiscal year. The market is reacting to a chart that has been running hot, while the income statement now shows the cleanest improvement in pure profit, which is where sentiment is being tested.

Love the clean profit rebound at Sigmakoki but wary of chasing a chart that already ran hard this month? Stack it up against 13 high quality undervalued stocks to see where earnings strength comes with a calmer entry point.

Q1 2027 Earnings Summary

  • Revenue (Q1 2027 vs. Q1 2026): ¥3,382 million vs. ¥2,505 million (higher period on period)
  • Net Income (Excl. Extra Items, Q1 2027 vs. Q1 2026): ¥373 million vs. ¥108 million (higher period on period)
  • Basic EPS (Q1 2027 vs. Q1 2026): ¥52.67 vs. ¥15.25 (higher period on period)
  • Trailing 12M Net Profit Margin (to Q1 2027 vs. prior 12M): 8.9% vs. 8.3% (margin level higher year on year)

Tired of scrolling through dense earnings tables and raw figures? View Sigmakoki’s complete financial profile and get a clear look at its recent profit trend in the visual company report for Sigmakoki.

TSE:7713 Trailing 12-Month Earnings & Revenue History as at Oct 2026
TSE:7713 Trailing 12-Month Earnings & Revenue History as at Oct 2026

Sigmakoki earnings momentum and bullish signals

Sigmakoki’s latest quarter lines up cleanly with a constructive view of the business. Revenue of ¥3,382 million and basic EPS of ¥52.67 both sit above the prior year’s Q1 levels, which supports the idea that demand across its optical and precision platforms is moving in the right direction. A trailing 12 month net profit margin of 8.9%, above the earlier 8.3%, signals better conversion of sales into earnings. For a picks and shovels supplier to automation, lasers and bio-medical tools, that combination of top line and margin traction fits a positive narrative.

Profit rebound, hot chart and bearish checks

The caution in the earlier narrative about cyclicality and a fast rising share price meets more mixed evidence. On the risk side, a 30 day return of 34.6% and 90 day move of 55.7% show sentiment already heated before and around the Q1 2027 release, so entry timing worries are understandable. At the same time, net income of ¥373 million and a firmer 8.9% trailing margin do not point to immediate pressure on the core model. In the near term, the financials appear steadier than the more anxious part of the story suggests.

After a 34.6% 30 day jump and a multi year earnings decline rate of 7.1% per year, the real question is whether this rebound masks deeper fragility. Review our independent risk analysis for Sigmakoki which shows 2 important warning signs

Stay Ahead Of Your Next Move

If Sigmakoki’s clean profit rebound and sharp 30 day share price jump have your attention, register for free with Simply Wall St and add it to a Watchlist to keep an eye on price versus fair value and wait for a setup that suits you. After taking a position, use the Portfolio Command Center to cut through noise and focus on the key events that matter to your holdings. For a longer term plan, tap into the crowd’s thinking through the Community and see how other investors are framing the same numbers. Spot potential catalysts and emerging risks earlier so you can act with confidence before the wider market catches up.

Seeking Fresh Alternatives Beyond Sigmakoki?

Market leadership can flip fast, and the strongest breakouts often move before screens get crowded. Scan focused lists of fresh ideas while the data still matters, then act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.